Shijiazhuang Yiling Pharmaceutical Co., Ltd.

SZSE:002603 Stock Report

Market Cap: CN¥27.2b

Shijiazhuang Yiling Pharmaceutical Management

Management criteria checks 2/4

Shijiazhuang Yiling Pharmaceutical's CEO is Xiang Jun Wu, appointed in Apr 2013, has a tenure of 11.67 years. directly owns 20.81% of the company’s shares, worth CN¥5.67B. The average tenure of the management team and the board of directors is 11.7 years and 8 years respectively.

Key information

Xiang Jun Wu

Chief executive officer

CN¥3.2m

Total compensation

CEO salary percentagen/a
CEO tenure11.7yrs
CEO ownership20.8%
Management average tenure11.7yrs
Board average tenure8yrs

Recent management updates

Recent updates

Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Business Is Trailing The Industry But Its Shares Aren't

Nov 26
Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Business Is Trailing The Industry But Its Shares Aren't

Shijiazhuang Yiling Pharmaceutical's (SZSE:002603) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 04
Shijiazhuang Yiling Pharmaceutical's (SZSE:002603) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Using Too Much Debt?

Sep 25
Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Using Too Much Debt?

Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Subdued P/S Might Signal An Opportunity

Aug 07
Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Subdued P/S Might Signal An Opportunity

Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Has Announced That Its Dividend Will Be Reduced To CN¥0.30

Jul 15
Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Has Announced That Its Dividend Will Be Reduced To CN¥0.30

Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) A Risky Investment?

May 26
Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) A Risky Investment?

Weak Statutory Earnings May Not Tell The Whole Story For Shijiazhuang Yiling Pharmaceutical (SZSE:002603)

May 05
Weak Statutory Earnings May Not Tell The Whole Story For Shijiazhuang Yiling Pharmaceutical (SZSE:002603)

Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Analysts Just Cut Their EPS Forecasts Substantially

May 02
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Analysts Just Cut Their EPS Forecasts Substantially

Should You Be Adding Shijiazhuang Yiling Pharmaceutical (SZSE:002603) To Your Watchlist Today?

Mar 01
Should You Be Adding Shijiazhuang Yiling Pharmaceutical (SZSE:002603) To Your Watchlist Today?

CEO

Xiang Jun Wu (49 yo)

11.7yrs

Tenure

CN¥3,154,300

Compensation

Mr. Xiang Jun Wu served as Deputy General Manager and Shijiazhuang Yiling Pharmaceutical Co., Ltd. and had been its Marketing Center General manager Since 2005. He is a Director since August 31, 2010 and G...


Leadership Team

NamePositionTenureCompensationOwnership
Xiang Jun Wu
Chairman & GM11.7yrsCN¥3.15m20.81%
CN¥ 5.7b
Chen Guang Li
CFO & Director6.7yrsCN¥1.83mno data
Wei Wang
Deputy GM & Director of Administrative Center13.9yrsCN¥944.90k0.12%
CN¥ 32.8m
Wei Dong Xu
Executive Deputy Director of the Human Resources Center & Directorno dataCN¥939.10k0.017%
CN¥ 4.7m
Rui Wu
Secretary of the Board & Non-Independent Director14.3yrsCN¥1.83m2.34%
CN¥ 637.7m
Qiu Lian Zhang
Deputy GM & Non-Independent Directorno dataCN¥2.16m0.017%
CN¥ 4.7m
Xiaolin Zhou
Deputy GM & Director of the Supply Center1.8yrsCN¥1.41m0.032%
CN¥ 8.6m

11.7yrs

Average Tenure

54yo

Average Age

Experienced Management: 002603's management team is seasoned and experienced (11.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Xiang Jun Wu
Chairman & GM14.3yrsCN¥3.15m20.81%
CN¥ 5.7b
Chen Guang Li
CFO & Director6.6yrsCN¥1.83mno data
Wei Dong Xu
Executive Deputy Director of the Human Resources Center & Director4.9yrsCN¥939.10k0.017%
CN¥ 4.7m
Rui Wu
Secretary of the Board & Non-Independent Director8yrsCN¥1.83m2.34%
CN¥ 637.7m
Qiu Lian Zhang
Deputy GM & Non-Independent Director4.9yrsCN¥2.16m0.017%
CN¥ 4.7m
Xue Dong Gao
Chairman of the Supervisory Board10.3yrsno data0.074%
CN¥ 20.2m
Shao Hua Zhao
Director11.7yrsCN¥971.80k0.037%
CN¥ 10.1m
Gen Wu Liu
Supervisor10.3yrsno data0.00065%
CN¥ 177.1k
Rui Hua Niu
Supervisor14.3yrsno datano data
Xiaohan Liu
Independent Director4.9yrsCN¥116.60kno data
Gang Chen
Independent Director1.8yrsCN¥100.00kno data

8.0yrs

Average Tenure

54yo

Average Age

Experienced Board: 002603's board of directors are considered experienced (8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 18:26
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shijiazhuang Yiling Pharmaceutical Co., Ltd. is covered by 19 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhengwu WuAJ Securities Co., Ltd
Shuchang LiuChangjiang Securities Co. LTD.
Weiying TuChina International Capital Corporation Limited